<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695484</url>
  </required_header>
  <id_info>
    <org_study_id>PRIME-AF</org_study_id>
    <nct_id>NCT03695484</nct_id>
  </id_info>
  <brief_title>Registry Evaluating AF Ablation Techniques</brief_title>
  <acronym>PRIME-AF</acronym>
  <official_title>Prospective, Multicenter, Non-randomized Observational Registry Conducted at High Volume Experienced Treatment Centers Utilizing the Most Current AF Ablation Techniques.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational registry is to prospectively collect procedure efficiency,
      safety and acute and long term outcome data from catheter ablation procedures as treatment of
      paroxysmal atrial fibrillation, using the following treatment modalities:

        -  Cryoballoon ablation

        -  Manual guided RF ablation using Contact Force catheters

        -  Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings

        -  Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Procedure time</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Procedure time (minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Fluoroscopy time (minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transseptal time</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Transseptal time (time from insertion of catheters until transseptal puncture) (minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left atrial dwell time</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Left atrial dwell time (time from LA entry until removal of catheters) (minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PVI ablation time</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>PVI ablation time (total PVI ablation time, i.e. first until last application) (minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ablation time per pulmonary vein</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Ablation time per pulmonary vein (minutes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First Pass Isolation</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>First Pass Isolation (i.e. Successful isolation of PVs after the first ablation attempt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Acute success (Successful electrical isolation of PVs at the end of procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TouchUp rates</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>TouchUp rates (additional applications for successful PV isolation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term success</measure>
    <time_frame>From the date of procedure until 1 year</time_frame>
    <description>Long-term success (freedom of atrial fibrillation 12 months after ablation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related adverse-events</measure>
    <time_frame>From the date of procedure until 7 days</time_frame>
    <description>Procedure-related adverse-events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term adverse events</measure>
    <time_frame>From the date of procedure until 1 year</time_frame>
    <description>Long-term adverse events</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>Manual guided RF ablation</arm_group_label>
    <description>Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <description>Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RMN guided RF ablation - High power</arm_group_label>
    <description>Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.
High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RMN guided RF ablation - Low power</arm_group_label>
    <description>Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.
Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for participation in the study have a reported incidence of at least two
        documented episodes of symptomatic paroxysmal atrial fibrillation during the three months
        preceding trial entry, as well as documentation of at least one episode of AF on ECG, and
        are eligible for PVI by catheter ablation based on the respective ACC/AHA/ESC Guideline
        valid at the date of procedure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented Paroxysmal Atrial Fibrillation

          -  Eligibility for Pulmonary Vein Isolation by catheter ablation based on the respective
             ACC/AHA/ESC Guideline valid at the date of procedure

          -  Signed the informed consent to participate in the registry

        Exclusion Criteria:

          -  Younger than 18 years of age

          -  Prior AF ablation procedure (including MAZE procedure)

          -  Prior ablation of Non-AF Arrhythmia within 3 months of enrollment

          -  Presence of cardiac thrombus

          -  Other AF ablations performed during procedure (e.g. lines, rotor, CFAE's etc)

          -  Active endocarditis or systemic infection

          -  Life expectancy &lt; 1 year

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna ME Noten, MD</last_name>
    <phone>+31107035018</phone>
    <email>a.noten@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T Szili-Torok, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>E. Meshalkin National medical research center</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Romanov, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Anne-Marie Noten</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>Cryoballoon</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Remote Magnetic Navigation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

